J. Biochem, 1989, Vol. 106, No. 1 87-92
© 1989 Japanese Biochemical Society
research-article |
Topographic Analysis of Human Epidermal Growth Factor by Monospecific Antibodies and Synthetic Peptides
Laboratory for Biochemistry, Pharma Research Laboratories, Hoechst Japan Limited Kawagoe, Saitama 350
The mode of interaction between human epidermal growth factor (hEGF) and its receptor has been investigated by immunochemical studies and a synthetic peptide approach. Two types of monoclonal and five different monospecific polyclonal antibodies against hEGF have been prepared, whose epitopes are regions 113, 1332, 3353, 3343, 2232, and discontinuous sequences of hEGF. Antibody against 2232 (Type I) and antibody against 3353 (PRE 4) inhibited the binding of 125I-hEGF to membrane receptor on A 431 cells more markedly than the other antibodies. When hEGF was bound to the receptor, only antibody against 1332 (PRE 2) could bind to hEGF-receptor complex whereas antibody against 2232 (Type I) could not. These data suggest that region 1320 is exposed outside during receptor-binding and both region 2232 and region 3353 contact the hEGF receptor. The activity of synthetic peptides corresponding to the amino acid residues 113, 1332, 3353, 1320, 2232, and 3343 of hEGF was also examined. Out of the six peptides, only 13 32 stimulated DNA synthesis of B ALB 3T3 cells. The activity was approximately 1/106 of that of intact hEGF. All of these data suggest that region 2232 is responsible for binding to the receptor for signal transduction and region 3353 binds to the receptor to stabilize the ligand-receptor interaction. This dual binding model fits in well with the three-dimensional hEGF structure deduced from NMR spectra.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
J. T. Jones, M. D. Ballinger, P. I. Pisacane, J. A. Lofgren, V. D. Fitzpatrick, W. J. Fairbrother, J. A. Wells, and M. X. Sliwkowski Binding Interaction of the Heregulinbeta egf Domain with ErbB3 and ErbB4 Receptors Assessed by Alanine Scanning Mutagenesis J. Biol. Chem., May 8, 1998; 273(19): 11667 - 11674. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. McInnes, D. W. Hoyt, R. N. Harkins, R. N. Pagila, M. T. Debanne, M. O'Connor-McCourt, and B. D. Sykes NMR Study of the Transforming Growth Factor-alpha (TGF-alpha )-Epidermal Growth Factor Receptor Complex. VISUALIZATION OF HUMAN TGF-alpha BINDING DETERMINANTS THROUGH NUCLEAR OVERHAUSER ENHANCEMENT ANALYSIS J. Biol. Chem., December 13, 1996; 271(50): 32204 - 32211. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Uematsu, M. Mogi, and T. Deguchi Interleukin (IL)-1{beta}, IL-6, Tumor Necrosis Factor-{alpha}, Epidermal Growth Factor, and {beta}2-Microglobulin Levels Are Elevated in Gingival Crevicular Fluid during Human Orthodontic Tooth Movement Journal of Dental Research, January 1, 1996; 75(1): 562 - 567. [Abstract] [PDF] |
||||
![]() |
A. Richter, D. R. Drummond, J. MacGarvie, S. M. Puddicombe, S. G. Chamberlin, and D. E. Davies Contribution of the Transforming Growth Factor alpha B-loop beta-Sheet to Binding and Activation of the Epidermal Growth Factor Receptor J. Biol. Chem., January 27, 1995; 270(4): 1612 - 1616. [Abstract] [Full Text] [PDF] |
||||

